Felycin-CA1 (Sirolimus Delayed-Release) Tablets for Cats, 12 tablets

Once-Weekly Cardiac Support for Cats

Product Description

Fight back with Felycin-CA1 (sirolimus delayed-release tablets). The first FDA conditionally approved, once-weekly drug for the management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy, or HCM. A silent killer of cats that affects one of every seven cats. Finally, screening cats to diagnose this disease early will help put an end to owners feeling powerless. The solution of Felycin-CA1 is the only disease-modifying drug for cats with HCM.

Benefits

• Proven safe with a reasonable expectation of effectiveness; Felycin-CA1 is the first and only disease-modifying drug for cats with HCM.
• Felycin-CA1 is administered once-weekly and is formulated specifically for cats in small tablet sizes for easy administration.
• Felycin-CA1 is an affordable treatment option for cat owners that may prevent and delay progressive LV hypertrophy that affects 1 in 7 cats.
• A conditionally approved drug is a designated by the FDA that is given when a product has been proven safe with a reasonable expectation of effectiveness based on the studies performed. This designation is often used by the FDA when there is an established need in disease states for which there is no other treatment option while the drug manufacturer continues to perform all required testing in larger cat populations.
• Felycin-CA1 is a prescription drug to be prescribed by a licensed veterinarian after a confirmed HCM diagnosis. Felycin-CA1 should not be used in cats with diabetes mellitus. Do not administer in cats with pre-existing liver disease.

Variants

• 0.4 mg tablet strength
• 1.2 mg tablet strength
• 2.4 mg tablet strength

Active Ingredient

Sirolimus (rapamycin)

How to Use

Directions

Felycin-CA1 (sirolimus delayed-release tablets) should be given orally daily as directed by your veterinarian with or without food.

Recommended Dosage Chart